• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Preliminary results of helical tomotherapy in patients with complex-shaped meningiomas close to the optic pathway.

作者信息

Schiappacasse Luis, Cendales Ricardo, Sallabanda Kita, Schnitman Franco, Samblas Jose

机构信息

Tomotherapy Department, Clinica La Milagrosa, IMO Group (Instituto Madrileno de Oncologia), Madrid, Spain.

出版信息

Med Dosim. 2011 Winter;36(4):416-22. doi: 10.1016/j.meddos.2010.10.003. Epub 2011 Mar 11.

DOI:10.1016/j.meddos.2010.10.003
PMID:21397487
Abstract

Meningiomas are the most common benign intracranial tumor. Meningiomas close to the optic pathway represent a treatment challenge both for surgery and radiotherapy. The aim of this article is to describe early results of helical tomotherapy treatment in complex-shaped meningiomas close to the optic pathway. Twenty-eight patients were consecutively treated. All patients were immobilized with a thermoplastic head mask and planned with the aid of a magnetic resonance imaging-computed tomography fusion. All treatments included daily image guidance. Pretreatment symptoms and acute toxicity were recorded. Median age was 57.5 years, and 92.8% patients had Eastern Cooperative Oncology Group performance status scale ≤1. The most common localizations were the sella turcica, followed by the cavernous sinus and the sphenoid. The most common symptoms were derived from cranial nerve deficits. Tomotherapy was administered as primary treatment in 35.7% of patients, as an adjuvant treatment in 32.4%, and as a rescue treatment after postsurgical progression in 32.1% patients. Most patients were either inoperable or Simpson IV. Total dose varied between 5000 and 5400 cGy; fractionation varied between 180 and 200 cGy. Median dose to the planning target volume was 51.7 Gy (range, 50.2-55.9 Gy). Median coverage index was 0.89 (range, 0.18-0.97). Median homogeneity index was 1.05 (range, 1-1.12). Acute transient toxicity was grade 1 and included headache in 35.7% patients, ocular pain/dryness in 28.5%, and radiation dermatitis in 25%. Thus far, with a maximal follow-up of 3 years, no late effects have been seen and all patients have a radiological stabilization of the disease. Helical tomotherapy offered a safe and effective therapeutic alternative for patients with inoperable or subtotally resected complex-shaped meningiomas close to the optic pathway. Acceptable coverage and homogeneity indexes were achieved with appropriate values for maximal doses delivered to the eyes, lenses, and chiasm, despite the proximity of the tumor to these structures.

摘要

相似文献

1
Preliminary results of helical tomotherapy in patients with complex-shaped meningiomas close to the optic pathway.
Med Dosim. 2011 Winter;36(4):416-22. doi: 10.1016/j.meddos.2010.10.003. Epub 2011 Mar 11.
2
Encouraging early clinical outcomes with helical tomotherapy-based image-guided intensity-modulated radiation therapy for residual, recurrent, and/or progressive benign/low-grade intracranial tumors: a comprehensive evaluation.基于螺旋断层放疗的图像引导调强放疗治疗残留、复发和/或进展性良性/低级别颅内肿瘤的早期临床结果:综合评价。
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):756-64. doi: 10.1016/j.ijrobp.2010.12.044. Epub 2011 Feb 23.
3
Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas : long-term experience and review of the literature.分次立体定向放射治疗良性海绵窦脑膜瘤:长期经验及文献综述
Strahlenther Onkol. 2006 Nov;182(11):635-40. doi: 10.1007/s00066-006-1548-2.
4
Helical tomotherapy for meningiomas of the skull base and in paraspinal regions with complex anatomy and/or multiple lesions.螺旋断层放疗用于治疗解剖结构复杂和/或存在多个病灶的颅底及脊柱旁区域脑膜瘤。
Tumori. 2011 Jul-Aug;97(4):484-91. doi: 10.1177/030089161109700412.
5
Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET.基于 MRI 和 68Ga-DOTATOC-PET 对脑膜瘤患者靶区勾画的前瞻性评估粒子治疗的早期治疗效果。
Acta Oncol. 2013 Apr;52(3):514-20. doi: 10.3109/0284186X.2013.762996. Epub 2013 Feb 12.
6
Stereotactic radiotherapy for treatment of cavernous sinus meningiomas.立体定向放射治疗海绵窦脑膜瘤
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11. doi: 10.1016/j.ijrobp.2003.09.003.
7
Optic toxicity in radiation treatment of meningioma: a retrospective study in 213 patients.脑膜瘤放射治疗中的视神经毒性:对213例患者的回顾性研究。
J Neurooncol. 2016 May;127(3):597-606. doi: 10.1007/s11060-016-2071-7. Epub 2016 Feb 6.
8
Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience.调强放射治疗(IMRT)用于复发性、残留性或未治疗的颅底脑膜瘤:初步临床经验。
Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72. doi: 10.1016/s0360-3016(02)03809-9.
9
Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas.适形调强质子放疗用于复发性、残留性或未经治疗的颅内脑膜瘤。
Radiother Oncol. 2004 Jun;71(3):251-8. doi: 10.1016/j.radonc.2004.02.011.
10
Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning.颅底脑膜瘤的粒子治疗后临床转归:主动扫描调强放疗的患者的毒性和局部控制
Radiat Oncol. 2018 Mar 27;13(1):54. doi: 10.1186/s13014-018-1002-5.

引用本文的文献

1
Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline.脑膜瘤放射治疗靶区勾画:ANOCEF 共识指南。
Radiat Oncol. 2023 Jul 5;18(1):113. doi: 10.1186/s13014-023-02300-w.
2
Efficacy and Tolerance of Intensity Modulated Radiation Therapy for Skull Base Meningioma.调强放射治疗颅底脑膜瘤的疗效与耐受性
Adv Radiat Oncol. 2019 Jul 23;4(4):587-595. doi: 10.1016/j.adro.2019.07.009. eCollection 2019 Oct-Dec.
3
Hypofractionated stereotactic radiation therapy in skull base meningiomas.颅底脑膜瘤的大分割立体定向放射治疗
J Neurooncol. 2015 Sep;124(2):283-9. doi: 10.1007/s11060-015-1838-6. Epub 2015 Jun 4.